Stryker In-Depth Value Investment Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging an existing pie, or creating an entirely new market?6/10

  A

  The ceiling is high, but Stryker is mainly enlarging and consolidating a huge existing pie, rather than creating a brand-new market from scratch. It is a share taker and category consolidator inside an established pool of medical-device demand, not an inventor of new demand.

  Start with the size and slope of the pie itself. Stryker spans multiple subsectors, including orthopedic implants, surgical instruments, endoscopy, neurovascular and vascular intervention, and in-hospital equipment. The global medical-device market is already worth hundreds of billions of dollars and has structural growth. Its long-term demand base comes from population aging, an exceptionally certain slow-moving variable: the World Health Organization expects that by 2030, 1 in every 6 people globally will be aged 60 or above, and by 2050 the population aged over 60 will double to about 2.1 billion; U.S. CDC data show that arthritis prevalence among U.S. adults is high and exceeds half of the population aged above 75. On this basis, the report gives the industry attractiveness a 4/5 score and notes that hip and knee replacement procedures should still grow significantly through 2040 and 2060. This slope is long and deep enough. That point fully holds.

  But what Baillie Gifford really wants to distinguish is whether the company is enlarging the pie or creating the pie. Stryker clearly belongs to the former. Its 2025 revenue was $25.116 billion (MedSurg and Neurotechnology $15.647 billion, or 62%; Orthopaedics $9.469 billion, or 38%). That revenue comes from taking share and upgrading categories inside the doctor-hospital-healthcare institution procurement chain that has existed for decades, using brand, clinical penetration, and product breadth. Its growth moves, including the 2025 acquisition of Inari to enter peripheral vascular and the 2026 acquisition of Amplitude to add IVL technology, are essentially purchases of adjacent markets where someone else has already validated demand, not the opening of a previously nonexistent market. The report is clear-eyed on this: competitors surround it in each segment (Zimmer Biomet, Medtronic, J&J MedTech, and CONMED in Instruments; Medtronic, J&J, Terumo, and Penumbra in Vascular/Neuro), and “Stryker is not a monopoly.”

  The closest thing to “creating a new market” is Mako surgical robotics reshaping the paradigm for orthopedic surgery. The report says Mako SmartRobotics now covers 45+ countries and has completed 2 million+ robotic procedures in total, including 1 million+ Mako Total Knee procedures; in 2026 it also launched the Mako RPS handheld robot. Robotic-assisted surgery is indeed changing the industry standard for how joint replacement should be done and raising the penetration ceiling. Still, it is making existing joint replacement procedures better and higher value. It is an upgrade and penetration story within an existing procedure base, not the creation of a new class of medical demand.

  Scored through the Baillie Gifford LTGG lens: the absolute height of the ceiling is high (a multi-trillion-dollar device pool driven by aging, with a long runway and deep snow), and this point is hard to criticize. But the quality of “creating a brand-new market” is relatively weak. Stryker is integrating share and upgrading categories inside a huge and certain existing pie, so the scarcity and explosiveness of its growth are lower than those of disruptors that truly define new categories. For a growth investor looking for “5x in 10 years,” the ceiling itself is not the constraint. The constraint is how quickly and efficiently Stryker can cut incremental value out of this large pie, rather than whether the market itself is large enough.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?4/10

  A

  Bottom line first: revenue at least doubling over the next five years is highly unrealistic. Given Stryker’s scale and historical growth rate, a five-year double would require roughly a 15% CAGR, while its revenue CAGR over the past five years (2021–2025) was only about 10%. A more plausible outcome is roughly 55%–65% five-year growth, from about $25.1 billion to about $39–41 billion. Structurally, growth is driven mainly by volume plus new-business M&A, with very little contribution from price.

  Start with the base and cadence. Stryker’s 2025 revenue was $25.116 billion, versus $22.595 billion in 2024 and $17.108 billion in 2021, implying a five-year revenue CAGR of about 10.1% (consistent with the report’s framing). Baillie Gifford asks whether it can double. The math is unforgiving: a five-year double requires 100% cumulative growth, or about 14.9% annualized. Even under an optimistic organic-growth plus acquisition scenario, there is little precedent for a $25 billion machine compounding at nearly 15% for five consecutive years. Management’s own 2026 full-year guidance is only 8.0%–9.5% organic growth and adjusted EPS of $14.90–15.10. That is high-single-digit organic growth. Reported growth may reach low double digits after acquisition consolidation, but it remains visibly short of the 15% needed for a double.

  The current short-term deceleration signal is also worth watching. In Q1 2026, affected by the March 11 cybersecurity incident, net sales were only $6.02 billion, up 2.6% year over year, with organic growth of 2.4% (2.1 percentage points from volume and 0.3 percentage points from price). Management described this as a one-off operational shock and maintained full-year guidance, but it is a reminder that treating high-single-digit growth as a steady-state floor itself carries operational fragility.

  Now split the three growth engines, which is the real target of this Baillie Gifford question. Stryker’s answer clearly leans toward volume plus new business, with price contributing almost nothing:

  • Volume (the main driver): Of the 2.4% Q1 organic growth, 2.1 percentage points came from volume. In 2025, Orthopaedics was “basically volume-driven, with near-zero price contribution” under the report’s framing. Behind volume growth are Mako installed-base pull-through for consumables and implants, aging-driven procedure volumes, and neurovascular penetration. This is a healthy but moderate growth source.

  • New business/M&A (the second-largest and most accelerative lever): In 2025 Stryker acquired Inari Medical to enter peripheral vascular, and in 2026 it acquired Amplitude to add IVL. Cash used for acquisitions in 2025 was about $5 billion. Under Kevin Lobo, Stryker has completed more than 60 acquisitions. Consolidating acquisitions is key to pushing reported growth from high single digits toward double digits, but it also means that “doubling” would depend on continuing to spend large sums to buy growth, rather than on pure internal compounding.

  • Price (almost no help): On a constant-currency basis in 2025, price contributed only about 1.1% of revenue growth (about 0.7% in MedSurg and close to zero in Orthopaedics), and in Q1 2026 price contributed only 0.3%. The report therefore characterizes Stryker as having “moderate pricing power, not price royalty.” It can absorb part of inflation, but raising prices is essentially not a path to doubling revenue.

  Scored honestly through the Baillie Gifford LTGG lens: this dimension is not outstanding. “At least doubling in five years” is a very hard, even unrealistic, threshold for Stryker. It is a high-quality compounding machine, but it is already large, and scale has diluted growth into the high-single-digit range. Five-year growth of around 60% is more plausible than a double. The growth mix of “volume plus M&A, with almost no price” also shows that growth is being pushed by scale and acquisition, not by irreplaceable pricing power plus explosive new demand. That is exactly how it differs from the kind of 5x-in-10-years growth stock Baillie Gifford truly prefers: steady, but not fast or scarce enough.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this “second curve” exist today?5/10

  A

  Bottom line first: Stryker’s “second curve” does exist today, and there is more than one. The clearest successors are peripheral vascular (entered through Inari/Amplitude) and the Mako robotics ecosystem (extending from Total Knee into handheld RPS, spine, and other new applications). But honestly, these second curves are still small, and the margin for error in peripheral vascular is thin. They can extend the life of the mature core business, but it is hard for them to independently support a new growth pole one order of magnitude larger.

  First define the core business and the urgency of needing a successor. Stryker’s current growth engines are two mature segments: MedSurg and Neurotechnology at $15.647 billion and Orthopaedics at $9.469 billion in 2025. These are mature pools growing at high single digits. Aging ensures they will not stall, but it also means they are unlikely to accelerate on their own. So “who takes over and accelerates growth” is a real question.

  Second curve 1: Peripheral Vascular, the most anticipated and also the most risk-concentrated curve. In 2025, Stryker completed the Inari Medical acquisition and formally created a Peripheral Vascular reporting unit to enter venous thromboembolism (VTE), a high-growth market. In 2026, it also signed and completed the acquisition of Amplitude Vascular Systems to add IVL (intravascular lithotripsy) technology. The strategic direction is right. It has real synergy with Stryker’s existing stroke/neurovascular platform and is not unrelated diversification. But this curve “exists yet remains fragile” today: the report says that in the 2025 impairment test, the reporting unit’s fair value was only 12% above carrying value, with goodwill of about $3.203 billion. In other words, it has the potential to become the next growth engine, but integration and profitability must be delivered. If growth or margins fall short of the acquisition assumptions, impairment may arrive before growth does.

  Second curve 2: deeper extension of the Mako robotics ecosystem, the curve with the strongest platform-regeneration quality. Mako is no longer a concept. The report says it covers 45+ countries and has completed 2 million+ robotic procedures in total, including 1 million+ Total Knee procedures. More importantly, it keeps expanding into new applications. In February 2026, Stryker launched the Mako RPS handheld robotic system for total knee replacement, and the fourth-generation Mako system also covers Total Hip, Partial Knee, and Spine. This means Mako is not merely consuming existing joint replacement volume. It is “roboticizing more procedures.” Each new application opens an additional growth curve and pulls through later consumables and upgrades. This is the part of Stryker that comes closest to the “platform that extends and regenerates itself” that Baillie Gifford prefers.

  Second curve 3, weaker and more supportive: neurovascular/stroke intervention and in-hospital digitalization (communications and virtual-care platforms). These provide diversified increments inside the portfolio, but they are not order-of-magnitude successors.

  The honest boundary is this: combined, these second curves are still small within a $25.1 billion revenue base, and the most anticipated peripheral vascular curve carries a thin goodwill cushion and integration uncertainty. The report already highlights a historical lesson: in 2024 the company recorded a $273 million goodwill impairment for the Spine reporting unit and ultimately sold part of the spinal implant business, proving that even promising directions may require strategic correction. So the second curve is not “absent.” It is “present but not yet proven capable of carrying acceleration, with real downside risk in one key leg.”

  Scored through the Baillie Gifford LTGG lens: this dimension is neutral to positive. The strength is that the second curve is already on the income statement and visible, not a future slide deck, and the Mako ecosystem has genuine platform-regeneration quality. The deductions are that these businesses remain small, peripheral vascular has a thin margin for error, and there is a historical strategic reversal in Spine. For a growth investor seeking “5x in 10 years,” this is a company with a stable core business and real but still undersized second curves that need continuous M&A funding. The successor engine exists, but whether it can ignite into an order-of-magnitude growth pole still needs to be proven by integration results over the next two or three years, not assumed today.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Bottom line first: Stryker’s core competitive advantage is a multilayered composite moat: brand and clinical trust, global direct-sales/distribution channels, regulatory and quality-system barriers, and switching costs created by the Mako robotics platform. It is not one single ultra-deep moat. Over the next three to five years, I judge the overall moat as stable to slightly widening: robotics/navigation/vascular platforms are widening it, while traditional orthopedic implants are more stable. Fundamentally, it lacks internet-style strong network effects, so the widening is gradual rather than step-change.

  First break down the layers of the moat and how hard each layer is:

  • Brand and clinical trust (real but not exclusive): In the doctor-hospital decision chain, once surgeons are used to a system, instrument set, or implant, they are reluctant to switch. Clinical data and training accumulated over time create stickiness. The report says this advantage “really exists,” but it is not exclusive like a patent, because competitors also have brands.

  • Scale and global channels (structural advantage): Stryker products are sold through owned subsidiaries, branches, and third-party dealers in about 61 countries, with most marketing directed to physicians and hospitals. This global multi-product direct-sales/distribution system is very hard for non-leading companies to challenge comprehensively. The report notes that non-leading companies find it hard to compete across globalization and multi-product coordination.

  • Regulatory, patent, and quality-system barriers (high entry barriers): Product design, manufacturing, sterilization, and marketing are governed by the FDA, EU MDR, and national regulators. New entrants must cross approval and quality-system thresholds. This is an industry-wide medical-device moat: protection for incumbents and a roadblock for entrants.

  • Mako platform switching costs (the layer with the most widening potential): This is what separates Stryker from an ordinary device manufacturer. The report says Mako SmartRobotics covers 45+ countries and has completed 2 million+ robotic procedures, including 1 million+ Total Knee procedures. Once a hospital installs Mako and surgeons are trained in its workflow, subsequent consumables, implants, upgrades, and new applications are locked in. Capital-equipment installation, workflow embedding, and training systems together create real switching costs, not a concept.

  But the ceiling of the moat needs to be stated honestly: it has no typical internet-style strong network effect and is not a low-cost leader. The report gives moat strength 4/5 and explicitly says it is “not a single ultra-deep moat.” It also operates in a highly competitive, not monopolistic, landscape. The report lists strong competitors in each segment: Zimmer Biomet, Medtronic, J&J MedTech, and CONMED in Instruments; Olympus, Smith+Nephew, Arthrex, and STERIS in Endoscopy; Medtronic, J&J, Terumo, and Penumbra in Vascular/Neuro. This means the moat is wider and deeper than many peers, not unattackable.

  Whether it widens or narrows over the next three to five years should be viewed by time frame and business line. This is the forward-looking lens Baillie Gifford wants, not a historical recap:

  • Widening areas: the Mako robotics plus navigation ecosystem. Each extension into a new procedure, such as the Mako RPS handheld system launched in 2026 and expansion into spine, spreads switching costs into a new use case and raises the catch-up threshold for competitors. The vascular platform is also broadening through the Inari/Amplitude acquisitions.
  • Stable areas: traditional orthopedic implants (joints and trauma). Demand is stable and share is stable, but competition is more commoditized and pricing power is weak (price contributed only 0.3% in Q1 2026). This is defense, not expansion.
  • Risk of narrowing: if Mako innovation slows and competitors such as Zimmer, J&J, and Medtronic, all with their own robotics efforts, catch up in robotics/navigation, the premium created by robotics will shrink. The report lists “Mako innovation slowing and leading to premium compression” as a first-tier risk.

  Scored through the Baillie Gifford LTGG lens: the moat dimension is one of Stryker’s relatively strong areas. It has multiple real layers that translate into 64% gross margin and high-single-digit steady-state growth, and the Mako layer has a clear path to continued widening, matching Baillie Gifford’s preference for moats that deepen over time. But it does not reach the top Baillie Gifford tier, such as Intuitive Surgical’s almost single-category ultra-deep robotics moat. The report’s relative valuation also shows the market assigning ISRG 53.2x and SYK 36.6x, which reflects the view that Stryker’s moat is wide but not the deepest. Conclusion: stable to slightly widening. It is a strength, but the increase in width is gradual and depends on the falsifiable premise that Mako remains ahead.

  Jun 11, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Bottom line first: Stryker shows the DNA of “incremental self-evolution plus facing bad news and making strategic corrections,” rather than the aggressive reinvention capability of a company that can rise from the ashes after its core is disrupted. Its attitude toward mistakes is relatively honest and pragmatic (it will proactively impair, exit failed businesses, disclose operational shocks, and maintain guidance), but we should be clear: it has never gone through a true existential crisis. Its so-called reinvention DNA is more “continuous M&A into new lanes plus platform extension” than a capability tested under extreme adversity.

  Start with the implicit premise in Baillie Gifford’s question: “If the core business is disrupted, does it have the DNA to reinvent itself?” Stryker’s core is orthopedic implants and surgical instruments. The realistic disruption scenario would most likely be robotics/navigation paradigms marginalizing traditional manual instruments, or a new technology replacing a specific segment. Stryker’s response is that it is itself one of the disruptors: it uses Mako to roboticize its own traditional joint replacement procedures, covering 2 million+ procedures, and in 2026 launched the Mako RPS handheld robot to iterate its own platform. That is incremental evolution by proactively disrupting itself, not passively waiting to be disrupted. Add Kevin Lobo’s more than 60 acquisitions and the continual push of business boundaries into high-growth lanes such as peripheral vascular, and its reinvention mechanism is “using capital allocation to keep changing or supplementing lanes.” This is real but moderate adaptability.

  How it handles mistakes and bad news is the more revealing part. The evidence points to honesty and no cover-up:

  • It will acknowledge mistakes, impair, and exit: The report says that in 2024 the company recorded a $273 million goodwill impairment for the Spine reporting unit and ultimately sold part of the spinal implant business. Management did not stubbornly carry an underperforming business. It acknowledged a capital-allocation mistake and made a strategic correction. That is a good governance signal: mistakes are handled through loss-cutting and adjustment, not concealment and doubling down.

  • Bad-news disclosure is transparent: The March 11, 2026 cybersecurity incident materially affected order processing, production, and shipping. Q1 gross margin was compressed to 63.3%, and adjusted operating margin contracted by about 180 basis points year over year. In the 10-Q, the company clearly disclosed that the gross-margin decline was “primarily due to production idle time related to the cybersecurity incident.” It did not blame vague “market conditions.” It quantified the impact and still maintained full-year guidance for 8.0%–9.5% organic growth and $14.90–15.10 EPS. Facing the problem, quantifying the impact, and avoiding whitewash are marks of responsible management.

  • The governance structure forces long-termism: The report says that in 2024, an average of 89% of NEO total direct compensation was variable, performance-based, and equity-related; the CEO is required to hold stock worth at least 5 times salary; executives are prohibited from hedging and pledging shares; and a clawback policy is in place. This system makes it harder for management to sacrifice the long term for short-term cosmetic results.

  But the boundaries must be stated honestly:

  1. It has not lived through a true existential crisis. Stryker’s revenue rose from $17.1 billion to $25.1 billion over five years, cash flow kept strengthening, and the balance sheet is sound (strong investment-grade ratings). Its “reinvention capability” has never been stress-tested in an extreme near-death corporate scenario. Baillie Gifford’s question of whether it can be reborn if the core is disrupted remains an unverified hypothetical for Stryker.
  2. The cybersecurity incident itself exposed operational fragility. The report treats it as evidence that “operational and IT system risk is not pure noise.” Rapid recovery is positive, but it shows a gap in resilience. “Self-repair” here is reactive remediation, not proactive immunity.
  3. Reinvention relies heavily on M&A as the path. If the M&A environment deteriorates or Stryker’s own share price falls and weakens its acquisition currency, this buy-and-build adaptation model will be constrained.

  Scored through the Baillie Gifford LTGG lens: this dimension is neutral. Stryker’s attitude toward mistakes and bad news is a positive: honest impairments, transparent disclosure, and governance that forces long-termism all fit the management character Baillie Gifford values. But its “reinvention DNA after core disruption” is not especially strong. It adapts through incremental iteration and continuous M&A, rather than phoenix-like rebirth, and that capability has never been tested by a true existential crisis. For a growth investor looking for 5x in 10 years, this is a steady, honest, self-correcting company, but not one that has proven it can be reborn through disruption. It is reliable, but lacks the extreme-adversity regeneration that Baillie Gifford prizes most.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for five to ten years from now?5/10

  A

  Bottom line first: management is a professional management team with a long-term view, rational governance, and material alignment with shareholders, but it is not an ultra-aligned founder-controlled structure. CEO Kevin Lobo’s equity value is meaningful relative to his compensation, but it represents only a very small percentage of the company. The true large-shareholder exposure comes from founder-family member Ronda E. Stryker’s roughly 4.6% stake. The company is willing to sacrifice the short term for the long term (continued high R&D investment and acquisition-led expansion rather than EPS-polishing buybacks), but the intensity of “sacrificing today’s profits for five to ten years out” is steady, not founder-like all-in commitment.

  First, the evidence on long-term orientation is positive:

  • Long tenure and long-term moves: Kevin Lobo has been CEO since October 2012 and chairman since July 2014. During his tenure, Stryker has completed more than 60 acquisitions and has pushed the business into long-runway areas such as Mako robotics and peripheral vascular.
  • Capital allocation is not serving short-term EPS: The 10-K states that long-term capital-allocation priorities are “M&A, dividends, and repurchases.” In 2025, cash used for acquisitions was about $5 billion, dividends paid were $1.284 billion, there were no repurchases in Q4, and about $1.033 billion of repurchase authorization remained at year-end. The report therefore judges that “repurchases are not Stryker’s main value-creation axis.” It is a compounding platform built on acquisition expansion, internal product iteration, and stable dividends, not a capital-return company using large buybacks to push EPS. That is exactly long-termism without financial engineering to beautify the short term.
  • It keeps investing instead of cutting to protect profits: The report notes that the company explicitly says in the 10-K that the competitive environment requires continuous R&D investment and maintenance of the sales force. It has not cut R&D or sales to polish current margins. That itself is evidence of “sacrificing today for five to ten years later.” Even after the Q1 2026 cybersecurity incident compressed adjusted operating margin by about 180 basis points, it maintained full-year guidance and did not protect the numbers by shrinking investment.

  Now look at whether interests are deeply aligned with the company. This is the core of Baillie Gifford’s question, and Stryker’s answer is “material alignment, but not deep alignment”:

  • The report discloses (based on the 2025 proxy, as of February 28, 2025) that Kevin Lobo directly held about 100,722 shares and had another approximately 1,111,481 shares obtainable within 60 days, totaling about 1,212,203 shares. At the current share price of about $309, this equity is worth about $370 million. That is immense personal wealth and real alignment, but relative to the company’s roughly $118.4 billion market cap, it is tiny, about 0.1%.
  • The true “family-level” exposure comes from Ronda E. Stryker, granddaughter of founder Homer Stryker. The report says she owns about 17.44 million shares, or about 4.6% of the company. That gives the company some founder-family long-term perspective, but she is a director/major shareholder, not the operating CEO.
  • The report’s judgment is apt: this is “not the super-shareholder structure of a founder still owning 20%–30% of the company, but it is absolutely not zero exposure by professional managers.” It is “substantive alignment, but not extremely strong alignment.”

  Governance terms are a clear positive, because they force management and shareholders into the same direction: The report says the company requires the CEO to hold shares worth at least 5 times salary, and other NEOs 3 times salary; in 2024, an average of 89% of NEO total direct compensation was variable, performance-based, and equity-related; the company prohibits executive hedging and pledging of shares; it has a clawback policy; and it has no employment or severance agreements and no contractual change-in-control payment arrangements. This “performance alignment + no hedging/pledging + no golden parachute” framework makes it hard for management to be paid regardless of outcomes and leans toward long-termism.

  Scored through the Baillie Gifford LTGG lens: this dimension is neutral to positive. The strengths are solid: long tenure, rational capital allocation, no buyback/R&D-cutting cosmetics, governance terms that pull interests toward shareholders, and founder-family long-term exposure of 4.6%. These all fit Baillie Gifford’s management requirements. But the depth of alignment is visibly weaker than in the founder or controlling-shareholder-led companies Baillie Gifford most loves. The CEO personally owns only about 0.1%, and this is fundamentally an excellent professional management team, not a founder with his or her net worth on the line. For a growth investor seeking 5x in 10 years, this means one can trust the team’s capability and character, but should not expect founder-like, cost-insensitive commitment to a distant vision. The report’s “management and capital allocation 3.5/5” is fair: respectable, but M&A quality must keep being verified.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulators?6/10

  A

  Bottom line first, from two angles: if Stryker disappeared tomorrow, customers would miss it considerably. Its products are deeply embedded in surgeons’ operating workflows and hospitals’ critical processes, so switching costs and clinical risk are high, but it is not uniquely irreplaceable because each segment has strong competitors that can partially substitute. Its growth model is highly healthy and sustainable and does not depend on harming society or regulators. Quite the opposite: its business is built on strict regulatory access and is aligned with the socially positive goal of making surgery more precise and improving patient outcomes. The answer to the first sub-question is “customers would miss it a lot, but it is not irreplaceable”; the answer to the second is “sustainable and able to withstand social and regulatory scrutiny.”

  First angle: how much would customers miss it, meaning indispensability. The answer is “high stickiness, but not exclusivity.”

  The sources of indispensability are concrete:

  • Switching costs embedded in surgical workflows: Mako robotics covers 45+ countries and has completed 2 million+ procedures, including 1 million+ Total Knee procedures. Once a Mako unit is installed in a hospital, surgeons become deeply tied to its workflow, preoperative planning, and training system. Removing it suddenly would directly disrupt surgical schedules and clinical processes. This combination of installed base, workflow embedding, and training makes seamless short-term substitution extremely difficult.
  • Supply continuity for critical consumables and implants: joints, trauma products, neurovascular implants, in-hospital transport, and emergency-care equipment all sit behind continuous and rigid clinical demand. Stryker products are supplied directly to physicians and hospitals in about 61 countries. A sudden disappearance would cause real supply and clinical disruption. The March 2026 cybersecurity incident already proved this in reverse: a brief stoppage in its own order, production, and shipping systems materially affected delivery and pushed Q1 gross margin down to 63.3%, showing how deeply customers depend on its delivery.

  But “not exclusive” must be marked honestly: Stryker is not a monopolist. The report lists strong competitors that can partially replace it in each segment: Zimmer Biomet, Medtronic, J&J MedTech, and CONMED in Instruments; Olympus, Smith+Nephew, Arthrex, and STERIS in Endoscopy; Medtronic, J&J, Terumo, and Penumbra in Vascular/Neuro. Customers would miss it a lot and migration would be painful, but the healthcare system would not collapse without Stryker. Competitors could gradually fill the gap over months to years. So the right framing is “highly missed, with high migration costs,” not “irreplaceable and the world stops.”

  Second angle: whether the growth model is sustainable and does not harm society or regulation, viewed through social legitimacy and regulatory sustainability.

  • Social dimension: growth is aligned with social benefit and does not rely on harm. Stryker’s demand base is real medical need driven by aging: the WHO expects that by 2030, 1 in 6 people globally will be over 60, and arthritis affects more than half of people over 75. It sells products that make joint replacement more precise (Mako), stroke intervention more timely, and hospital operations more efficient. Faster growth theoretically means more patients receiving better surgical outcomes. This is a business where greater success implies more positive social utility. There is no internal conflict of “profiting by harming others,” unlike models built on addiction, information abuse, or shifting externalities.

  • Regulatory dimension: it is not “arbitraging around regulation,” but “using regulation as a moat,” which makes sustainability stronger. The report notes that Stryker’s product design, manufacturing, sterilization, marketing, and sales are all governed by the FDA, EU MDR, and national regulators. Its growth is built on passing these strict approvals. Regulation is an entry barrier, not something it is trying to evade. That means its growth model can withstand regulatory scrutiny, and high compliance requirements protect leaders while raising barriers for new entrants.

  But the sustainability risks in the regulatory/social dimension must be listed truthfully. Baillie Gifford wants honesty, not beautification:

  1. Recall and quality risk is an inherent tail risk of this business. The report lists “regulatory, quality, and recall risk” as a second-tier risk. Any quality-system failure, label update, recall, or compliance error would directly erode profits and damage social trust. The “missed by customers” quality of medical devices is a double-edged sword: the more indispensable the product, the greater the social cost of a major quality incident.
  2. Moderate pricing power also means it is not growing by over-raising prices and harming the healthcare system. Price contributed only 0.3% in Q1 2026, with growth mainly driven by volume. This is actually positive for social sustainability: the company is not extracting hospital budgets, but growing through procedure penetration and category upgrades.

  Scored through the Baillie Gifford LTGG lens: this dimension is positive overall. Indispensability is high but not top-tier: customers would miss it greatly and migration costs are high, but every segment has strong substitutes, so it does not reach Intuitive Surgical’s near-exclusive indispensability. Growth sustainability is a clear strength: it is aligned with aging and the social goal of improving patient outcomes, uses regulation as a moat rather than an arbitrage target, and does not grow by harming society. For a growth investor seeking 5x in 10 years, this is a company with strong social legitimacy, strong regulatory sustainability, high customer stickiness, and no monopoly. It is clean, long-term, and durable under scrutiny; the one internal tail risk that needs ongoing monitoring is recall/quality.

  Jun 11, 2026
• QHow are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate as scale increases? Where does the money it earns go?7/10

  A

  Bottom line first: Stryker’s unit economics are high-quality and stable. Gross margin has long stayed around 63%–64%, capital intensity is low (about 3% of sales), cash conversion is better than accounting profit, and as scale increases the unit economics basically remain stable with slight improvement (operating margin benefits from scale absorption), rather than materially deteriorating or taking a major leap. The money it earns mainly goes to M&A (the largest use), dividends (steadily growing), and limited repurchases. These are the cash characteristics of a high-quality compounding machine, but the slope of incremental returns is gently upward, not steep.

  Gross margin: high and extremely stable. This is the base color of the unit economics. Stryker’s five-year gross margin has barely moved: 64.1% in 2021, 63.9% in 2024, and about 64.0% in 2025. Holding gross margin at 64% while revenue rose from $17.1 billion to $25.1 billion shows that its product mix (high-value implants + capital equipment + consumables) has structurally high gross margin and that scale expansion has not diluted unit profitability. The only disturbance is cyclical/event-driven: in Q1 2026, production idle time caused by the cybersecurity incident compressed gross margin to 63.3%. That was a one-off operational shock and does not change the 64% steady-state center.

  Do unit economics improve or deteriorate as scale increases? The answer is “stable with slight improvement,” visible in the rise in operating margin: The key is whether operating margin improves as scale absorbs costs. The evidence says yes. Operating margin rose from 15.1% in 2021 to 19.5% in 2025 (gross margin barely moved, but operating margin improved by about 4 percentage points). This shows that as revenue grows, selling, administrative, R&D, and other expenses are being absorbed by scale, and operating-level unit economics are improving slowly. Scale brings positive operating leverage. This is healthy “larger and somewhat more profitable,” but the magnitude is moderate, not explosive marginal-margin expansion.

  Incremental returns and cash conversion are high quality, which is the report’s most important point:

  • Cash conversion consistently exceeds accounting profit: 2025 operating cash flow of $5.044 billion was significantly above net income of $3.246 billion; free cash flow was $4.283 billion, and FCF/net income reached about 132%. Under the report’s framing, operating cash flow has exceeded net income throughout the past five years. Profit is not “paper profit,” which is hard evidence of high-quality unit economics. (2025 GAAP net margin was depressed by one-off factors: the effective tax rate rose to 28.1% because of cross-jurisdiction intellectual-property transfers, far above 14.3% in 2024, and $732 million of intangible amortization made GAAP profit look noisier, while cash flow was not affected.)
  • Capital intensity is low: capital expenditure has long been about 3% of sales (total 2025 capex $761 million). The report therefore judges that “this business does not become more capital-hungry as it grows.” Incremental revenue does not require proportional heavy-asset investment, which is a good incremental-return feature.
  • Returns on capital are excellent but not top-tier: The report roughly estimates 2025 ROE at about 15%, and the relative valuation table lists SYK ROE at 15.2%. That is mid-teens, better than Medtronic (9.39%) and Zimmer (6.07%), but below Intuitive Surgical (17.23%). It is excellent capital return, not extreme capital return.

  Where does the money it earns go? The answer is clear and skewed toward acquisition-led expansion: The 10-K states that long-term capital-allocation priorities are “M&A, dividends, and repurchases,” and the 2025 cash flow confirms that order:

  • M&A (the largest use): cash used for acquisitions was about $5 billion (Inari and others), the clear central axis;
  • Dividends (continuously growing): dividends paid were $1.284 billion, and the report says the dividend record has continued to grow;
  • Repurchases (smallest, not the main axis): there were no repurchases in Q4, and about $1.033 billion of repurchase authorization remained at year-end. The report judges that “repurchases are not Stryker’s main value-creation axis.” It is not a capital-return company using buybacks to polish EPS; it mainly reinvests cash into acquisition-led expansion.

  The honest boundary: putting the largest cash use into M&A means the quality of incremental returns increasingly depends on acquisition returns. The report has already warned that the Peripheral Vascular reporting unit containing Inari had fair value only 12% above carrying value in the 2025 impairment test, with goodwill of $3.203 billion, and that Spine saw a $273 million impairment in 2024. In other words, the internal unit economics are clean, but there is real execution risk around whether the money is spent well.

  Scored through the Baillie Gifford LTGG lens: unit economics are one of Stryker’s stronger dimensions. A 64% gross margin, low capex, cash conversion above 100%, mid-teens ROE, and positive operating leverage from scale are a textbook high-quality compounding-machine combination, fully consistent with Baillie Gifford’s requirements for an excellent business. There are two deductions: first, the slope of incremental returns is moderate (margin improvement from scale is gradual rather than explosive); second, the largest cash use is M&A, so unit-economics quality is increasingly tied to acquisition returns. Conclusion: the business-quality dimension is firmly supported and is one of the company’s most testable strengths. But it is a “steady high-quality” business, not exponential unit economics where the larger it gets, the more profitable it becomes.

  Jun 11, 2026
• QWhat conditions must all hold for it to rise 5x in 10 years? Are those conditions realistic? What expectations does today’s share price imply?2/10

  A

  Bottom line first: for Stryker to rise 5x in 10 years (about 17.5% annualized total return), three things would need to happen at the same time: revenue/profit must grow about 2.6x over 10 years, the valuation multiple must not contract, and dividends must be reinvested along the way. Given its current scale of about $25.1 billion in revenue, high-single-digit organic growth, and already elevated valuation (about 36x P/E, far above most large-cap device peers), this set of conditions is not realistic and belongs in the “very low probability” bucket. Today’s share price implies the opposite: the company must keep executing high-single-digit growth nearly perfectly, and the market must keep assigning a high valuation premium for a long time. It does not leave new capital with a cheap mispricing.

  First break “5x in 10 years” into the conditions that must all hold. This is the realism test Baillie Gifford wants:

  5x = about 1.175^10. Splitting the return sources, the following things must happen simultaneously:

  1. Earnings/cash flow must grow at least about 2.6x over 10 years (≈10% annualized), and the valuation multiple must not move down. If the multiple holds, the share price broadly follows EPS. But Stryker’s revenue CAGR over the past five years was only about 10.1%, and management’s own 2026 organic growth guidance is only 8.0%–9.5%. Even if M&A pushes reported growth into the low double digits and operating leverage lifts profit growth slightly above revenue growth, sustaining roughly 10%+ earnings compounding for 10 straight years is already an excellent upper bound. That only gets the stock to about 2.6x, still far short of 5x.

  2. The valuation multiple must not contract, and may even need to expand. This is the least realistic link. Stryker’s current P/E is about 35.7x, 36.6x under the report’s framing, and the relative valuation table shows it is already materially above MDT 22.0x, ZBH 22.2x, and BSX 24.2x. For a 10-year 5x, earnings must not only grow 2.6x; the multiple also needs to barely fall. Yet a mature large-cap device leader with slowing growth is more likely over the long run to revert toward the “mature large-device average” of 25–30x or even lower, which would directly subtract a large portion from the 5x outcome.

  3. No major impairment, recall, or integration failure can occur over 10 years. The Peripheral Vascular reporting unit’s fair value was only 12% above carrying value in the 2025 impairment test, with goodwill of $3.203 billion. Any impairment like the $273 million Spine charge in 2024, or a larger integration failure, would interrupt compounding.

  4. Dividend reinvestment must contribute a little over 1% annualized. The current dividend yield is about 1.1%. Long-term reinvestment helps a little, but it is a drop in the bucket. It cannot bridge the huge gap between “earnings grow 2.6x” and “the stock needs to grow 5x.”

  Are these conditions realistic? The honest answer is no. Multiplying the four conditions above, a 10-year 5x requires near-tripling of earnings, no valuation decline, zero major accidents, and dividend reinvestment all landing together. Stryker’s organic growth rate (high single digits) is enough to support a base case of roughly 2.6x earnings over 10 years. The report’s own expected annualized-return framework is sober: conservative 6%–7%, neutral 7%–8.5%, optimistic 8.5%–10%. Even the most optimistic 10% annualized scenario is only about 2.6x over 10 years, far from “5x”. So “5x in 10 years” for Stryker is not merely “challenging”; it is basically not on the table.

  What does today’s share price imply? This is the real focus of this Baillie Gifford question, and the answer is “full, even pulled forward” expectations:

  • The report anchors on a more credible “reasonable intrinsic value range” of $230–300 per share and notes that the current price still carries about a 19% premium to the midpoint of that range. Note: the current share price has retreated from the report snapshot of $316.48 to about $309, so the premium has narrowed slightly, but it still sits near the upper end of the reasonable range.
  • Using conservative Owner Earnings of about $4.3 billion and a market cap of about $118.4 billion, the current valuation is about 28x Owner Earnings, and the Owner Earnings yield is only about 3.5%. The 10-year U.S. Treasury yield is about 4.57% under the report’s framing. The starting cash return is even below the risk-free rate, which means all excess return from buying today is being staked on future growth being delivered.
  • In other words, the current price implies that the company must maintain mid- to high-single-digit organic growth for a long time, execute acquisitions smoothly without impairments, and keep receiving a valuation premium versus peers. That is a full set of “must keep executing perfectly” assumptions, not a discount from the market being wrong and offering a bargain. The report’s conclusion is sharp: buying now means “betting that it continues to do many things right, not exploiting mispricing the market has handed you.”

  Scored through the Baillie Gifford LTGG lens: this dimension, the hard threshold for “5x in 10 years,” clearly does not pass. The required conditions, near-tripling earnings, no valuation compression, and zero major accident, are unrealistic for a mature leader with $25 billion in revenue, high-single-digit growth, and a 36x valuation. Today’s price not only lacks a margin of safety; it embeds full expectations of “continuous perfect execution plus a sustained high valuation premium.” Owner Earnings yield, at about 3.5%, is even below the risk-free rate. For a growth investor seeking 5x in 10 years, Stryker sits at the key Baillie Gifford intersection of “growth explosiveness × valuation attractiveness” as a classic “good company, bad price.” That is also the core reason the report gives a “Watch” rather than “Buy” rating.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Is it because the market does not understand it, looks down on it, or cannot look far enough? What will become the “narrative inflection point”?3/10

  A

  Bottom line first, with the key reversal: for Stryker, the premise of this Baillie Gifford question needs to be inverted. The market has not “failed to recognize how good it is.” Quite the opposite: the market understands its strengths well and has fully priced them in. Its current P/E of about 36x, materially above most large-cap device peers, is itself evidence that the market has long recognized that Mako is good, orthopedics is good, vascular expansion is good, and management is good. There is no cognitive-discount gap caused by “does not understand / looks down on / cannot look far enough.” The real narrative inflection point is unlikely to be upward value discovery, and more likely to be downward: growth deceleration or acquisition impairment could rewrite the story from “high-quality growth platform” to “expensive mature device stock.”

  Apply Baillie Gifford’s three-part framework (does not understand / looks down on / cannot look far enough) one by one. The conclusion is that none applies:

  • Not “does not understand”: Stryker’s business is extremely transparent and easy to understand: orthopedic implants + surgical instruments + neurovascular + in-hospital equipment, with demand driven by aging. The report gives business understandability 4.5/5. It is not so complex that the market cannot understand it and therefore misprices it downward. On the contrary, it is a heavily covered large-cap blue chip that institutions have studied repeatedly.

  • Not “looks down on it”: The market not only does not look down on Stryker; it gives it a clear premium. Relative valuation shows SYK at about 36.6x P/E (currently about 35.7x), far above Medtronic 22.0x, Zimmer Biomet 22.2x, and Boston Scientific 24.2x. The report notes that the market acknowledges Stryker’s better growth, brand, robotics platform, and capital returns, which is why it gets a premium. This is a “respected” valuation, not a disliked discount.

  • Not “cannot look far enough”: The market has already priced in the long-term stories: the Mako robotics platform (covering 45+ countries and 2 million+ procedures), the new peripheral vascular lane, and the long aging runway. The report’s bear-case framing is blunt: this is a “high-quality but fully narrated crowded medical-device stock.” “Mako is good, orthopedics is good, vascular expansion is good, and management is decent. The market knows all of it.” The market is not failing to look far; it has already pulled the long-term optimistic scenario into today’s valuation.

  So what has the market “not realized”? Downside risk, not upside value. What may truly be underappreciated is not how good Stryker is, but how unattractive the return/risk tradeoff is at the current price. That is exactly the report’s core judgment: the current price implies “continuous perfect execution plus a long-term high valuation premium.” Owner Earnings yield is only about 3.5%, even below the 10-year U.S. Treasury yield (about 4.57%). The market has fully priced the “good,” but may be underpricing how future returns compress when a good company becomes expensive, as well as tail risk from acquisition integration. The report gives “valuation below intrinsic value = fail” and “sufficient margin of safety = fail.”

  What will the narrative inflection point be? This is the “inflection point” Baillie Gifford asks for, and the direction is more likely downward:

  • Downside inflection point (the bigger concern): ① A visible impairment in peripheral vascular/Inari. The reporting unit’s 2025 impairment-test fair value was only 12% above carrying value, with goodwill of $3.203 billion. If growth or margins miss assumptions, impairment could become the trigger that rewrites the “platform expansion” narrative into a “high-priced acquisition” narrative; the 2024 Spine $273 million impairment was already a preview. ② Sustained core organic-growth deceleration below the industry average. Q1 2026 organic growth had already fallen to 2.4% because of the cybersecurity incident. If deceleration proves structural rather than one-off, the market will quickly re-rate the multiple from 36x toward the “mature device average” of 25–30x. ③ Mako is caught by competitors and the robotics premium compresses. These would all collapse the narrative from “high-quality growth” toward “mature large-cap,” corresponding to the report’s estimated 30%–45% downside space.

  • Upside inflection point (real but weaker): The only thing that could turn today’s “Watch” into “Buy,” as the report says clearly, is not that the company becomes better (the market already knows it is good), but that the price falls back into a more reasonable range (ideal buy zone $185–230 per share), while vascular integration goes smoothly, Mako expansion continues, and high-single-digit growth proves sustainable. In other words, wait for market sentiment to cool and offer a better entry point, not for the market to suddenly discover Stryker’s value.

  Scored through the Baillie Gifford LTGG lens: this is Stryker’s weakest dimension and the one most contrary to the Baillie Gifford pattern. Baillie Gifford’s core question is “why has the market not realized all this yet?” Stryker’s honest answer is: “the market realized it long ago and has fully, even richly, priced it.” There is no cognitive-discount gap for a growth investor to capture. Quite the opposite, the potential inflection points are downside ones (impairment, deceleration, premium compression), not upward value discovery. For a growth investor seeking 5x in 10 years, a stock whose strengths are universally known, whose valuation premium is already pulled forward, whose cognitive gap is absent, and whose inflection risk skews downward is exactly the type Baillie Gifford would politely put on a watchlist for a better price, not buy heavily today. That is fully consistent with the report’s final “Watch” rating and its advice to use patience on price rather than linearly extrapolating the quality premium.

  Jun 11, 2026